Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05130970 · ClinicalTrials.gov registry record · Phase 2
Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis
A Phase 2 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT05130970 is a Phase 2 study that has completed, run by CSL Behring. The registered enrollment target is 81 participants.
The verdict
NCT05130970, a Phase 2 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of garadacimab in subjects with idiopathic pulmonary fibrosis (IPF).
Interventions
- DRUG Placebo
- DRUG Garadacimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2022-02-03 |
| Est. Completion | 2024-01-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05130970
The ClinicalTrials.gov registry entry for NCT05130970 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05130970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05130970 about?
NCT05130970 is a clinical study titled "Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis". This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of garadacimab in subjects with idiopathic pulmonary fibrosis (IPF).
What is the current status of trial NCT05130970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2022-02-03. Estimated completion is 2024-01-02.
What interventions are being tested in trial NCT05130970?
The interventions under investigation include: Placebo (DRUG), Garadacimab (DRUG).
Who is sponsoring clinical trial NCT05130970?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.